Clinical trial
Quetiapine and the Dopaminergic Epigenetic Control
NCT00370500 · University of Erlangen-Nürnberg Medical School, Other · Completed
Key facts
| NCT number | NCT00370500 |
|---|---|
| Title | Quetiapine and the Dopaminergic Epigenetic Control |
| Official title | Quetiapine and the Dopaminergic Epigenetic Control - a Pilot Study |
| Lead sponsor | University of Erlangen-Nürnberg Medical School, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Quetiapine fumarate |
| Enrollment | 100 |
| Start date | Apr 1, 2007 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Aug 31, 2006 |
| Last update posted | Dec 14, 2020 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: